Union Bancaire Privee UBP SA Invests $693,000 in iShares Biotechnology ETF (NASDAQ:IBB)

Posted by Emily Schoerning on Jan 29th, 2025

Union Bancaire Privee UBP SA purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,485 shares of the financial services provider’s stock, valued at approximately $693,000.

A number of other large investors have also added to or reduced their stakes in IBB. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth $29,000. Highline Wealth Partners LLC purchased a new stake in iShares Biotechnology ETF during the third quarter valued at about $30,000. Ashton Thomas Securities LLC bought a new position in iShares Biotechnology ETF during the third quarter worth about $36,000. Modus Advisors LLC purchased a new position in shares of iShares Biotechnology ETF in the fourth quarter worth about $41,000. Finally, Voisard Asset Management Group Inc. bought a new stake in shares of iShares Biotechnology ETF in the third quarter valued at approximately $59,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 0.2 %

IBB opened at $138.16 on Wednesday. iShares Biotechnology ETF has a 12 month low of $123.60 and a 12 month high of $150.57. The company has a 50 day moving average of $136.25 and a 200 day moving average of $141.72.

iShares Biotechnology ETF Cuts Dividend

The business also recently declared a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were given a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.